Skip to main content
lexblog.com/lib/KT4WN8CXviewrecordjson
{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "Switching Study Concludes That Transition From Humira To Samsung Bioepis’s Adalimumab Biosimilar Is Safe and Effective",
    "url": "https://www.lexblog.com/2022/03/03/switching-study-concludes-that-transition-from-humira-to-samsung-bioepiss-adalimumab-biosimilar-is-safe-and-effective/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-KT4WN8CX",
        "url": "https://www.lexblog.com/lib/KT4WN8CX/"
    },
    "datePublished": "2022-03-03T16:59:26-05:00",
    "dateModified": "2022-03-03T16:59:29-05:00",
    "author": {
        "@type": "Person",
        "name": "Emily Rapalino"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Goodwin Procter"
    },
    "organizationScope": "at-publication",
    "isPartOf": "Big Molecule Watch",
    "about": "Health Care and Life Sciences",
    "sourceUrl": "https://www.bigmoleculewatch.com/2022/03/03/switching-study-concludes-that-transition-from-humira-to-samsung-bioepiss-adalimumab-biosimilar-is-safe-and-effective/",
    "sourceStability": "may-move"
}